trending Market Intelligence /marketintelligence/en/news-insights/trending/-1ozLo8mdraXZd_-qR8NxA2 content esgSubNav
In This List

ThromboGenics shareholders approve name change

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


ThromboGenics shareholders approve name change

Belgium-based biotechnology company ThromboGenics NV gained shareholders approval to change its name to Oxurion NV at an extraordinary general meeting held Sept. 3.

ThromboGenics' lead product JETREA is used to treat declining visual function due to vitreomacular traction syndrome.

The company's ticker on Euronext Brussels will change to OXUR from THR.

ThromboGenics said in a statement that it will also change its corporate website in connection with the name change.